Read More Healthcare Industry News Boston Scientific (BSX) Q2 2026 beats estimates as MiRus TAVR investment reshapes strategy Boston Scientific lifted FY 2026 guidance and disclosed a $1.5B MiRus TAVR bet, but BSX trades near 52-week lows as softer Q3 growth guidance stings. byVenkateshJuly 29, 2026